Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.

S'inscrire

TSHA Taysha Gene Therapies Inc

1,88

0,14 (8,05%)

03 Jan 2025 - Fermé

Retardé de 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

The Reporting Person is selling the securities set forth herein pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted stock unit awards only.

Date of Notice

07/05/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Sean McAuliffe

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Taysha Gene Therapies (NASDAQ:TSHA)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025

Plus de graphiques de la Bourse Taysha Gene Therapies

Taysha Gene Therapies (NASDAQ:TSHA)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025

Plus de graphiques de la Bourse Taysha Gene Therapies

Actualités Taysha Gene Therapies Inc

Form EFFECT - Notice of Effectiveness
Lundi 23 Décembre 2024 ( il y a 2 semaines) • Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933
Vendredi 13 Décembre 2024 ( il y a 3 semaines) • Edgar (US Regulatory)

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vendredi 6 Décembre 2024 ( il y a 4 semaines) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Mercredi 13 Novembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Mercredi 13 Novembre 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Vendredi 8 Novembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Taysha Gene Therapies to Release Third Quarter 2024 Financial Results and Host Conference Call and Webcast On November 13
Mercredi 6 Novembre 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vendredi 1 Novembre 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Taysha Gene Therapies to Present Biodistribution Data from an Analysis Evaluating AAV9 Gene Therapy Delivery at the Upcoming 31st Annual ESGCT Congress
Mardi 22 Octobre 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vendredi 4 Octobre 2024 ( il y a 3 mois) • GlobeNewswire Inc.

Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress
Jeudi 26 Septembre 2024 ( il y a 3 mois) • GlobeNewswire Inc.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vendredi 6 Septembre 2024 ( il y a 4 mois) • GlobeNewswire Inc.

Plus d'articles sur Taysha Gene Therapies Inc

Lvmh Moet Hennessy Louis...

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales